AMBER’s topline resilience (13–15% Consumer Durables, 79% Electronics growth) and margin expansion (Electronics double-digit FY27) hinge on execution of INR 6,800 Cr capex pipeline and commodity pass-through, with structural risks skewed to integration delays and cyclical RAC demand.
📊 Base Case (50% Probability)
KAYNES’ topline hinges on project execution timing (Kavach, aerospace) and ODM adoption; bottomline sensitive to working capital normalization and subsidy-driven capex phasing; margins require ODM scale-up to sustain expansion beyond 16%. FY28 $1 billion target viable but contingent on structural ODM/OSAT execution.
📊 Base Case (50% Probability)
Key Variables: Kavach executes in Q4; OSAT/PCB Phase 1 completes by FY27.
Outcome: FY26 revenue at INR 4,000 crore; EBITDA margin at 16% on throughput leverage. OCF turns positive in FY27 as receivables normalize. OSAT contributes INR 1,000 crore by FY28, PCB adds INR 800 crore; EMS grows at 25% CAGR. $1 billion FY28 revenue achieved, but margin expansion lags due to ODM ramp-up.
LAURUSLABS: ARV-led generics and CDMO drive 15–25% growth, but biotech drag limits upside. EBITDA margins (26–28%) hinge on utilization and FX gains; ROCE recovery (18.5%→20–22%) rests on asset turnover. Gross margin at 60% needs ARV/CDMO mix, with risk of 55% under price pressure.
📊 Base Case (50% Probability)